{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:49:10Z","timestamp":1793638150049,"version":"4.5.1"},"reference-count":100,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2026,7,3]]},"DOI":"10.1080\/14656566.2026.2695100","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T03:11:01Z","timestamp":1782357061000},"page":"995-1008","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Emerging synthetic drugs for the management of hidradenitis suppurativa: a comprehensive update"],"prefix":"10.1080","volume":"27","author":[{"given":"Daifallah","family":"Almansouri","sequence":"first","affiliation":[{"name":"Universitaetsklinikum Ruppin-Brandenburg, Brandenburg Medical School Theodor Fontane","place":["Neuruppin, Germany"]},{"name":"Taif University","place":["Taif, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Naasani","sequence":"additional","affiliation":[{"name":"Dermatologist and Venereologist","place":["Dessau, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos C.","family":"Zouboulis","sequence":"additional","affiliation":[{"name":"Universitaetsklinikum Ruppin-Brandenburg, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg","place":["Neuruppin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14214"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.4161\/derm.2.1.12490"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.1677"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1159\/000136656"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.07.046"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.05.015"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14038"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.01.059"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16677"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.6264"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17578"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504370"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00022-3"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00101-6"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01487-y"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0149-1"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02965"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2009.00915.x"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.12788\/j.sder.2017.017"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.07.045"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.09.012"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13449"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16428"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.953674"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14056"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.12.651"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16147"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.05.033"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.139930"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.70163"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18465"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00791-1"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2018.03.041"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16019"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.201900586"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1089\/wound.2014.0559"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17769"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00054.2016"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15255"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0502-4"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-015-0134-5"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.01.085"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.25251\/skin.8.supp.473"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20969"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.10.034"},{"key":"e_1_3_4_48_1","volume-title":"34th European Academy of Dermatology and Venereology (EADV) Congress","author":"Porter ML","year":"2025","unstructured":"Porter ML, Martorell A, Sayed CJ, et al. Povorcitinib for moderate\u2011to\u2011severe hidradenitis suppurativa: 24\u2011week interim results from the phase 3 STOP\u2011HS program. In: 34th European Academy of Dermatology and Venereology (EADV) Congress. Paris, France; European Academy of Dermatology and Venereology; 2025. p. #D1T01.1C."},{"key":"e_1_3_4_49_1","unstructured":"European Medicines Agency. Rinvoq: EPAR \u2013 product information and medicine overview. [updated 2025 Apr 14]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rinvoq"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.047"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.12.046"},{"key":"e_1_3_4_52_1","unstructured":"U.S. Food and Drug Administration. OPZELURA (ruxolitinib) cream prescribing information. 2025 [updated 2025 Sep]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215309s007lbl.pdf"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2022.104499"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae495"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.10.149"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-023-01454-2"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.99323"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222543"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.11.027"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300155"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106642"},{"key":"e_1_3_4_62_1","unstructured":"ClinicalTrias.gov. Evaluating the safety and efficacy of deucravacitinib compared to placebo hidradenitis suppurativa (HS). [updated 2026 May 29]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05997277"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X19828669"},{"key":"e_1_3_4_64_1","unstructured":"European Medicines Agency. Otezla: EPAR \u2013 product information and medicine overview. [updated 2024 Oct 22]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/otezla"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000018991"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.06.046"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18818"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-01054-3"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19770"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15748"},{"key":"e_1_3_4_71_1","unstructured":"ClinicalTrials.gov. Orismilast for the treatment of mild to severe hidradenitis suppurativa (OSIRIS). [updated 2021 Sep 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04982432"},{"key":"e_1_3_4_72_1","unstructured":"U.S. Food and Drug Administration. ZORYVE (roflumilast) topical foam 0.3% prescribing information. 2025. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217242s000lbl.pdf"},{"key":"e_1_3_4_73_1","unstructured":"ClinicalTrials.gov. The safety and efficacy of roflumilast foam. [updated 2026 Feb 11]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07263230"},{"key":"e_1_3_4_74_1","unstructured":"ClinicalTrials.gov. A study for evaluating safety & efficacy of topical roflumilast 0.3% foam in hidradenitis suppurativa (NCT07077902). [updated 2025 Mar 18]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07077902"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000004298"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.10.089"},{"key":"e_1_3_4_77_1","unstructured":"Novartis Pharmaceuticals. A phase 3 study to assess efficacy safety and tolerability of remibrutinib in adult patients with moderate to severe hidradenitis suppurativa (RECHARGE\u20111 \/ RECHARGE\u20112). 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06799000"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.10.007"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-022-01135-0"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.05.076"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2023.10.005"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20061825"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.04.035"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02635-7"},{"key":"e_1_3_4_85_1","unstructured":"ClinicalTrials.gov. A phase 2 study to evaluate the efficacy and safety of SAR444656 compared with placebo in adult participants with moderate to severe hidradenitis suppurativa (ZEN). [updated 2025 Dec 11]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06028230"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/bip.21292"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2024.1405339"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1128897"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.4800"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11517"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.2147\/CPAA.S305308"},{"key":"e_1_3_4_92_1","unstructured":"ClinicalTrials.gov. ATI\u2011450 vs placebo in patients with moderate to severe hidradenitis suppurativa (HS) [ATI\u2011450\u2011HS\u2011201]. [updated 2026 Jan 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05216224"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18877"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf398"},{"key":"e_1_3_4_95_1","unstructured":"ClinicalTrials.gov. Evaluate safety and pharmacokinetics of INF904 in subjects with moderate to severe chronic spontaneous urticaria or hidradenitis suppurativa NCT06555328. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06555328"},{"key":"e_1_3_4_96_1","unstructured":"InflaRx. 11\u20132025-InflaRx reports positive phase 2a data for INF904 in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). 2025. Available from: https:\/\/www.inflarx.de\/Home\/Investors\/Press-Releases\/11-2025-InflaRx-Reports-Positive-Phase-2a-Data-for-INF904-in-Hidradenitis-Suppurativa--HS--and-Chronic-Spontaneous-Urticaria--CSU-.html"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1002\/jvc2.70268"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103818"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2025.2484022"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10061303"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae399"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1177\/12034754241300292"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2026.2695100","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14656566.2026.2695100","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2026.2695100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:37:56Z","timestamp":1784115476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2026.2695100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":100,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,7,3]]}},"alternative-id":["10.1080\/14656566.2026.2695100"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2026.2695100","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-05-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}